Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TRIPLEX TO FILE FIRST TRIPLE HELIX IND DURING 1993

Executive Summary

TRIPLEX TO FILE FIRST TRIPLE HELIX IND DURING 1993 for an antiviral indication, the company said in a March 18 prospectus for an initial public offering. "Depending on the results of its preclinical research, the company plans to file an IND for either [herpes simplex virus] or HIV in 1993," the prospectus says. Triplex has two lead compounds against HSV-1 (B-116 and B-108), one targeting HSV-2 (B-106) and one targeting the AIDS virus (HIV- 38), the prospectus says. Triplex' antiviral research program is backed by a $30 mil. collaboration with Hoechst AG announced in January ("The Pink Sheet" Feb. 3, T&G-4). The deal grants Hoechst rights to a limited number of undisclosed viral targets. Hoechst made a $3 mil. payment to Triplex at the close of the deal on Jan. 1 and has an option to pay $2 mil. more for an equity stake in the company (615,385 shares if Hoechst exercises its option prior to the offering, substantially less if it exercises the option subsequently). Hoechst also has made $400,000 in research payments through March 15, the prospectus says. Triplex' "technology is based upon scientific evidence that oligonucleotides can bind to the major groove of the DNA double helix to form a triple helix" and block transcription, the prospectus says. Triplex contrasts this technology to antisense, which involves blocking messenger RNA to prevent protein synthesis. Triplex maintains "that, in many instances, antisense approaches may be rendered ineffective by the cell's own efficient mRNA control mechanism." Triple helix technology could require smaller doses since it acts directly on one DNA site rather than on "thousands" of mRNA copies, the prospectus maintains. Several companies working on antisense, including Gilead and Genta, also have triple helix (or "triple strand") research programs. Triplex has rights to four pending patent applications which "cover the basic technology of triple helix formation using certain oligonucleotides which specifically bind to target sites in double helical DNA molecules," the prospectus says. Triplex has spent $2.8 mil. on R&D since its founding in May 1989. In addition to its lead antiviral compounds, the company has identified lead compounds as potential treatments for breast cancer, colon cancer and post-angioplasty restenosis. Triplex also has research programs targeting cytomegalovirus, human papillomavirus and hepatitis B. The Woodlands, Texas-based Triplex is seeking at least $25 mil. from the offering of 2.5 mil. shares, which it expects will fund operations through the end of 1995. Underwriters are First Boston and J. P. Morgan. Former Glaxo exec James Chubb, PhD, serves as Triplex' CEO. Former Sterling-Winthrop VP-Licensing and Acquisitions Chistopher Kelly is Triplex' VP-commercial development. VP-Molecular and Biological Research Gregory Reyes, MD/PhD, joined in March from Genelabs, where he was VP of molecular biology. The company's director of finance and administration is Ray Webb.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel